MedTrace Logo

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

NCT00354562 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2011-01-07

No results posted yet for this study

Summary

To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.

Conditions

Interventions

DRUG

ABT-751

200mg ABT-751 daily for 14 days every 21 days

DRUG

Placebo

Placebo daily for 14 days every 21 days

DRUG

Docetaxel

Standard Docetaxel every 21 days

Sponsors & Collaborators

Principal Investigators

  • Helen Eliopoulos, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-02-29

Countries

  • United States
  • Canada
  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354562 on ClinicalTrials.gov